Mostra el registre parcial de l'element

dc.contributor.authorCampayo, Marc
dc.contributor.authorNavarro, Alfons
dc.contributor.authorVinolas Segarra, Nuria
dc.contributor.authorDíaz Sánchez, Tània
dc.contributor.authorTejero-Villalba, Rut
dc.contributor.authorGimferrer Garolera, Josep M
dc.contributor.authorMolins, Laureano
dc.contributor.authorCabañas Leon, Maria Luisa
dc.contributor.authorRamírez, Jose
dc.contributor.authorMONZO, MARIANO
dc.contributor.authorMarrades Sicart, Ramon
dc.date.accessioned2026-05-29T14:27:56Z
dc.date.issued2013-04-30
dc.identifier.citationCampayo, Marc; Navarro, Alfons; Viñolas, Nuria[et al.]. Low miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancer, European Respiratory Journal, 2013, 41(5), páginas 1172–1178. Disponible en <https://publications.ersnet.org/content/erj/41/5/1172>. Fecha de acceso: 29 may. 2026. DOI: 10.1183/09031936.00048712ca
dc.identifier.issn1399-3003ca
dc.identifier.urihttps://hdl.handle.net/20.500.12328/5350
dc.descriptionThis work was supported by grants from Fondo de Investigacio´n Sanitaria (FIS 080135, 09 00547), Sociedad Espan˜ola de Neumologı´ay Cirugı´a Tora´cica (SEPAR 809-2009) and Societat Catalana de Pneumologia (SOCAP 2009). T. Diaz is a fellow supported by Age`ncia de Gestio´ d’Ajuts Universitaris i de Recerca (AGAUR), Generalitat de Catalunya and Fondo Social Europeo. R. Tejero is a fellow of the University of Barcelona.ca
dc.description.abstractABSTRACT: The transcription factors SRY-related HMG box (SOX)2 and octamer-binding transcription factor (OCT)4 regulate the expression of the miR-302–367 cluster. miR-145 regulates SOX2 and OCT4 translation and p53 regulates miR-145 expression. We analysed the expression of the miR-302–367 cluster and miR-145 and the mutational status of p53 in resected nonsmall cell lung cancer (NSCLC) patients and correlated results with time to relapse (TTR). Tumour and paired normal tissue samples were obtained from 70 NSCLC patients. MicroRNA expression was assessed with TaqMan MicroRNA Assays. p53 exons 5 to 8 were sequenced. miR-145 was downregulated (p,0.0001) and miR-367 was upregulated (p,0.0001) in tumour compared with normal tissue. Mean TTR was 18.4 months forpatients with low miR-145 levels and 28.2 months for those with high levels (p50.015). Mean TTR was 29.1 months for patients with low miR-367 levels and 23.4 months for those with high levels (p50.048). TTR was shorter for patients with both unfavourable variables (p50.009). Low miR-145 expression (p50.049), the combination of unfavourable microRNA levels (p50.02) and the combination of low miR-145 with p53 mutations (p50.011) were independent markers of shorter TTR. In conclusion, miR-145 and miR-367 expression could be novel markers for relapse in surgically treated NSCLC. p53 may play a role in modulating miR-145 expression in NSCLC.ca
dc.format.extent7ca
dc.language.isoengca
dc.publisherERSca
dc.relation.ispartofEuropean Respiratory Journalca
dc.relation.ispartofseries41;5
dc.rights@ ERS 2013ca
dc.subject.othermiR-145ca
dc.subject.othermiR-367ca
dc.subject.otherNonsmall cell lung cancerca
dc.subject.otherp53ca
dc.subject.otherprognostic markersca
dc.subject.otherCáncer de pulmón de células no pequeñasca
dc.subject.otherMarcadores pronósticosca
dc.subject.otherCàncer de pulmó de cèl·lules no petitesca
dc.subject.otherMarcadors pronòsticsca
dc.titleLow miR-145 and high miR-367 are associated with unfavourable prognosis in resected nonsmall cell lung cancerca
dc.typeinfo:eu-repo/semantics/articleca
dc.description.versioninfo:eu-repo/semantics/publishedVersionca
dc.rights.accessLevelinfo:eu-repo/semantics/embargoedAccess
dc.embargo.termsforeverca
dc.subject.udc616ca
dc.identifier.doihttps://doi.org/10.1183/09031936.00048712
dc.date.embargoEnd9999-01-01


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.

Aquest element apareix en la col·lecció o col·leccions següent(s)

Mostra el registre parcial de l'element

Comparteix a TwitterComparteix a LinkedinComparteix a FacebookComparteix a TelegramComparteix a WhatsappImprimeix